DOCSLIB.ORG

Mifepristone (Korlym)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Mifepristone (Korlym) Drug and Biologic Coverage Policy Effective Date ............................................ 1/1/2021 Next Review Date… ..................................... 1/1/2022 Coverage Policy Number ............................... IP0092 Mifepristone (Korlym®) Table of Contents Related Coverage Resources Overview .............................................................. 1 Coverage Policy ................................................... 1 Reauthorization Criteria ....................................... 2 Authorization Duration ......................................... 2 Conditions Not Covered....................................... 2 Background .......................................................... 3 References .......................................................... 4 INSTRUCTIONS FOR USE The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer’s particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer’s benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer’s benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. In certain markets, delegated vendor guidelines may be used to support medical necessity and other coverage determinations. Overview This policy supports medical necessity review for mifepristone (Korlym®) Coverage Policy Mifepristone (Korlym®) is medically necessary when ALL of the following are met: 1. Individual is 18 years of age or older 2. Mifepristone (Korlym®) is prescribed by or in consultation with an endocrinologist or a physician who specializes in the treatment of Cushing’s syndrome 3. Individual has ONE of the following: a. Documented Endogenous Cushing’s Syndrome and BOTH of the following: • Mifepristone (Korlym®) is being used to control hyperglycemia secondary to hypercortisolism in individuals who have type 2 diabetes mellitus or glucose intolerance • According to the prescriber, the individual is not a candidate for surgery or surgery has not been curative Page 1 of 4 Coverage Policy Number: IP0092 b. Documented Endogenous Cushing’s Syndrome with hyperglycemia - Individual Awaiting Surgery • Mifepristone (Korlym®) is being used to control hyperglycemia secondary to hypercortisolism in individuals who have type 2 diabetes mellitus or glucose intolerance c. Documented Endogenous Cushing’s Syndrome - Individual Awaiting Response After Radiotherapy • Mifepristone (Korlym®) is being used to control hyperglycemia secondary to hypercortisolism in individuals who have type 2 diabetes mellitus or glucose intolerance When coverage is available and medically necessary, the dosage, frequency, duration of therapy, and site of care should be reasonable, clinically appropriate, and supported by evidence-based literature and adjusted based upon severity, alternative available treatments, and previous response to therapy. Note: Receipt of sample product does not satisfy any criteria requirements for coverage. Documentation: When documentation is required, the prescriber must provide written documentation supporting the trials of these other agents. Documentation may include, but is not limited to, chart notes, prescription claims records, and/or prescription receipts Reauthorization Criteria Mifepristone (Korlym®) is considered medically necessary for continued use when initial criteria are met AND there is documentation of beneficial response (such as an improvement in fasting glucose, oral glucose tolerance, or hemoglobin A1c results). Authorization Duration Initial and reauthorization is as follows unless otherwise stated: • Endogenous Cushing’s Syndrome: Approve for 1 year • Endogenous Cushing’s Syndrome – Individuals Awaiting Surgery: Approve for 6 months • Endogenous Cushing’s Syndrome – Individuals Awaiting Therapeutic Response After Radiotherapy: Approve for 6 months Conditions Not Covered Mifepristone (Korlym®) is considered experimental, investigational or unproven for ANY other use including the following (this list may not be all inclusive): 1. Exogenous (Iatrogenic) Cushing’s Syndrome. Korlym is not indicated in exogenous Cushing’s syndrome. Exogenous Cushing’s syndrome is caused by excessive glucocorticoid administration.12 Therefore, the process to reverse the excessive cortisol exposure is to taper or discontinue the offending drug when possible. 2. Type 2 Diabetes Not Associated with Endogenous Cushing’s Syndrome. Korlym should not be used for the treatment of type 2 diabetes unrelated to endogenous Cushing’s syndrome.1 3. Psychotic Features of Psychotic Depression. Mifepristone has been used to treat the psychotic features of psychotic depression. Individual trials have demonstrated variable efficacy results.3,10-11,15,18 In some of the studies comparing mifepristone with placebo, various statistically significant improvements in psychiatric symptoms have been noted with mifepristone relative to placebo; however, the methodology and statistical analyses of some studies have been questioned.14 Data are inconclusive. Page 2 of 4 Coverage Policy Number: IP0092 Background FDA Approved Indication Korlym (mifepristone) is a cortisol receptor blocker indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. Limitations of use: Korlym should not be used in the treatment of patients with type 2 diabetes unless it is secondary to Cushing’s syndrome. FDA Recommended Dosing The recommended starting dose is 300 mg orally once daily. Korlym must be given as a single daily dose. Korlym should always be taken with a meal. Patients should swallow the tablet whole. Do not split, crush, or chew tablets. The daily dose of Korlym may be increased in 300 mg increments. The dose of Korlym may be increased to a maximum of 1200 mg once daily but should not exceed 20 mg/kg per day. Increases in dose should not occur more frequently than once every 2-4 weeks. Decisions about dose increases should be based on a clinical assessment of tolerability and degree of improvement in Cushing’s syndrome manifestations. Drug Availability Korlym (mifepristone) is available as 300 mg tablet. OVERVIEW Korlym is a cortisol receptor blocker indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.1 Korlym should not be used for the treatment of type 2 diabetes mellitus unrelated to endogenous Cushing’s syndrome. Mifepristone, the active ingredient in Korlym is also available as Mifeprex® (mifepristone 200 mg tablets) indicated for the medical termination of intrauterine pregnancy through 70 days’ pregnancy.2 Mifeprex is not included in this policy. Mifepristone, the active ingredient in Korlym is a selective antagonist of the progesterone receptor (PR) at low doses and blocks the glucocorticoid type 2 receptor (GR-II) at higher doses.1 Mifepristone has high affinity for the GR-II receptor but little affinity for the GR-I (mineralocorticoid) receptor (MR). In addition, mifepristone appears to have little or no affinity for estrogen, muscarinic, histaminic, or monoamine receptors. Mifepristone acts at the receptor level to block the effects of cortisol, and its antagonistic actions affect the hypothalamic-pituitary-adrenal (HPA) axis in such a way as to further increase circulating cortisol levels while at the same time blocking their effects. Mifepristone and its three active metabolites have greater affinity for the glucocorticoid receptor (100%, 61%, 48%, and 45%, respectively) than either dexamethasone (23%) or cortisol (9%). Endogenous Cushing’s Syndrome Endogenous Cushing’s syndrome is a rare heterogeneous disorder with diverse causes that leads to cortisol excess (hypercortisolism).3 Patients with Cushing’s syndrome exhibit a variety of signs and symptoms such as high blood pressure, diabetes, loss of libido, menstrual disorders, weight gain, hirsutism, acne, easy bruising, purplish skin striae, osteoporosis, muscle weakness, depression
Load more

Recommended publications
  • Mifepristone
    1. NAME OF THE MEDICINAL PRODUCT Mifegyne 200 mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 200-mg mifepristone. For the full list of excipients, see section 6.1 3. PHARMACEUTICAL FORM Tablet. Light yellow, cylindrical, bi-convex tablets, with a diameter of 11 mm with “167 B” engraved on one side. 4. CLINICAL PARTICULARS For termination of pregnancy, the anti-progesterone mifepristone and the prostaglandin analogue can only be prescribed and administered in accordance with New Zealand’s abortion laws and regulations. 4.1 Therapeutic indications 1- Medical termination of developing intra-uterine pregnancy. In sequential use with a prostaglandin analogue, up to 63 days of amenorrhea (see section 4.2). 2- Softening and dilatation of the cervix uteri prior to surgical termination of pregnancy during the first trimester. 3- Preparation for the action of prostaglandin analogues in the termination of pregnancy for medical reasons (beyond the first trimester). 4- Labour induction in fetal death in utero. In patients where prostaglandin or oxytocin cannot be used. 4.2 Dose and Method of Administration Dose 1- Medical termination of developing intra-uterine pregnancy The method of administration will be as follows: • Up to 49 days of amenorrhea: 1 Mifepristone is taken as a single 600 mg (i.e. 3 tablets of 200 mg each) oral dose, followed 36 to 48 hours later, by the administration of the prostaglandin analogue: misoprostol 400 µg orally or per vaginum. • Between 50-63 days of amenorrhea Mifepristone is taken as a single 600 mg (i.e. 3 tablets of 200 mg each) oral dose, followed 36 to 48 hours later, by the administration of misoprostol.
    [Show full text]
  • Comparing the Effects of Combined Oral Contraceptives Containing Progestins with Low Androgenic and Antiandrogenic Activities on the Hypothalamic-Pituitary-Gonadal Axis In
    JMIR RESEARCH PROTOCOLS Amiri et al Review Comparing the Effects of Combined Oral Contraceptives Containing Progestins With Low Androgenic and Antiandrogenic Activities on the Hypothalamic-Pituitary-Gonadal Axis in Patients With Polycystic Ovary Syndrome: Systematic Review and Meta-Analysis Mina Amiri1,2, PhD, Postdoc; Fahimeh Ramezani Tehrani2, MD; Fatemeh Nahidi3, PhD; Ali Kabir4, MD, MPH, PhD; Fereidoun Azizi5, MD 1Students Research Committee, School of Nursing and Midwifery, Department of Midwifery and Reproductive Health, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic Of Iran 2Reproductive Endocrinology Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic Of Iran 3School of Nursing and Midwifery, Department of Midwifery and Reproductive Health, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic Of Iran 4Minimally Invasive Surgery Research Center, Iran University of Medical Sciences, Tehran, Islamic Republic Of Iran 5Endocrine Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic Of Iran Corresponding Author: Fahimeh Ramezani Tehrani, MD Reproductive Endocrinology Research Center Research Institute for Endocrine Sciences Shahid Beheshti University of Medical Sciences 24 Parvaneh Yaman Street, Velenjak, PO Box 19395-4763 Tehran, 1985717413 Islamic Republic Of Iran Phone: 98 21 22432500 Email: [email protected] Abstract Background: Different products of combined oral contraceptives (COCs) can improve clinical and biochemical findings in patients with polycystic ovary syndrome (PCOS) through suppression of the hypothalamic-pituitary-gonadal (HPG) axis. Objective: This systematic review and meta-analysis aimed to compare the effects of COCs containing progestins with low androgenic and antiandrogenic activities on the HPG axis in patients with PCOS.
    [Show full text]
  • Ketoconazole (Systemic) | Memorial Sloan Kettering Cancer Center
    PATIENT & CAREGIVER EDUCATION Ketoconazole (Systemic) This information from Lexicomp® explains what you need to know about this medication, including what it’s used for, how to take it, its side effects, and when to call your healthcare provider. Brand Names: Canada APO-Ketoconazole; Ketoconazole-200; TEVA-Ketoconazole Warning This drug is not for use to treat certain types of fungal infections. This includes fungal infections of the skin, nails, or brain. Talk with the doctor. This drug must only be used when other drugs cannot be used or have not worked. Talk with your doctor to be sure that the benefits of this drug are more than the risks. Very bad and sometimes deadly liver problems like the need for a liver transplant have happened with this drug. Some people did not have a raised chance of liver problems before taking this drug. Most of the time, but not always, liver problems have gone back to normal after this drug was stopped. Call your doctor right away if you have signs of liver problems like dark urine, feeling tired, not hungry, upset stomach or stomach pain, light-colored stools, throwing up, or yellow skin or eyes. Blood tests will be needed to watch for any liver problems. Talk with your doctor. Taking this drug with certain other drugs may raise the chance of very bad and sometimes deadly heart problems like a heartbeat that is not normal. Do not take this drug if you are taking any of these drugs: Cisapride, disopyramide, dofetilide, dronedarone, methadone, pimozide, quinidine, or ranolazine. Ketoconazole (Systemic) 1/6 What is this drug used for? It is used to treat fungal infections.
    [Show full text]
  • Treatment of Peripheral Precocious Puberty
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by IUPUIScholarWorks Treatment of Peripheral Precocious Puberty Melissa Schoelwer, MD and Erica A Eugster, MD Section of Pediatric Endocrinology, Department of Pediatrics, Riley Hospital for Children, Indiana University School of Medicine, Indianapolis, Indiana Send correspondence to: 705 Riley Hospital Drive, Room 5960 Indianapolis, IN 46202 Phone: 317-944-3889 Fax: 317-944-3882 Email: [email protected] __________________________________________________________________________________________ This is the author's manuscript of the article published in final edited form as: Schoelwer, M., & Eugster, E. A. (2016). Treatment of Peripheral Precocious Puberty. In Puberty from Bench to Clinic (Vol. 29, pp. 230-239). Karger Publishers. http://dx.doi.org/10.1159/000438895 Peripheral Precocious Puberty Abstract There are many etiologies of peripheral precocious puberty (PPP) with diverse manifestations resulting from exposure to androgens, estrogens, or both. The clinical presentation depends on the underlying process and may be acute or gradual. The primary goals of therapy are to halt pubertal development and restore sex steroids to prepubertal values. Attenuation of linear growth velocity and rate of skeletal maturation in order to maximize height potential are additional considerations for many patients. McCune-Albright syndrome (MAS) and Familial Male-Limited Precocious Puberty (FMPP) represent rare causes of PPP that arise from activating mutations in GNAS1 and the LH receptor gene, respectively. Several different therapeutic approaches have been investigated for both conditions with variable success. Experience to date suggests that the ideal therapy for precocious puberty secondary to MAS in girls remains elusive. In contrast, while the number of treated patients remains small, several successful therapeutic options for FMPP are available.
    [Show full text]
  • CYP3A4 Mediated Pharmacokinetics Drug Interaction Potential of Maha
    www.nature.com/scientificreports OPEN CYP3A4 mediated pharmacokinetics drug interaction potential of Maha‑Yogaraj Gugglu and E, Z guggulsterone Sarvesh Sabarathinam1, Satish Kumar Rajappan Chandra2 & Vijayakumar Thangavel Mahalingam1* Maha yogaraja guggulu (MYG) is a classical herbomineral polyherbal formulation being widely used since centuries. The aim of this study was to investigate the efect of MYG formulation and its major constituents E & Z guggulsterone on CYP3A4 mediated metabolism. In vitro inhibition of MYG and Guggulsterone isomers on CYP3A4 was evaluated by high throughput fuorometric assay. Eighteen Adult male Sprague–Dawley rats (200 ± 25 g body weight) were randomly divided into three groups. Group A, Group B and Group C were treated with placebo, MYG and Standard E & Z guggulsterone for 14 days respectively by oral route. On 15th day, midazolam (5 mg/kg) was administered orally to all rats in each group. Blood samples (0.3 mL) were collected from the retro orbital vein at 0.25, 0.5, 0.75, 1, 2, 4, 6, 12 and 24 h of each rat were collected. The fndings from the in vitro & in vivo study proposed that the MYG tablets and its guggulsterone isomers have drug interaction potential when consumed along with conventional drugs which are CYP3A4 substrates. In vivo pharmacokinetic drug interaction study of midazolam pointed out that the MYG tablets and guggulsterone isomers showed an inhibitory activity towards CYP3A4 which may have leads to clinically signifcant interactions. Te use of alternative medicine such as herbal medicines, phytonutrients, ayurvedic products and nutraceuticals used widely by the majority of the patients for their primary healthcare needs.
    [Show full text]
  • PROCUR Why Procur Has Been Prescribed for You
    Consumer Medicine Information Ask your doctor if you have any questions about PROCUR why Procur has been prescribed for you. Cyproterone acetate 50 mg and 100 mg tablets This medicine is available only with a doctor's prescription. What is in this leaflet Before you take Procur Please read this leaflet carefully before you start taking Procur When you must not take it This leaflet answers some common questions about Procur. It does not contain all the available Do not take Procur if you have an allergy to: information. It does not take the place of talking • any medicine containing cyproterone acetate to your doctor or pharmacist. • any of the ingredients listed at the end of this leaflet All medicines have risks and benefits. Your doctor has weighed the risks of you taking Procur against Some of the symptoms of an allergic reaction may the benefits they expect it will have for you. include: • difficulty in breathing or wheezing If you have any concerns about taking this • shortness of breath medicine, ask your doctor or pharmacist. • swelling of the face, tongue, lips, or other parts of the body Keep this leaflet with the medicine. You may • hives on the skin, rash, or itching need to read it again. Do not take Procur if: What Procur is used for • you are allergic to cyproterone acetate or any other ingredient listed at the end of this leaflet Procur tablets contain the active ingredient • you are pregnant cyproterone acetate. Cyproterone acetate is an • you are breastfeeding antiandrogen. It works by blocking the actions of • you suffer from liver diseases (including sex hormones (androgens) that are produced previous or existing liver tumours, Dubin- mainly in men but also, to a lesser extent in Johnson syndrome or Rotor syndrome) women.
    [Show full text]
  • Studies on the Interactions Between Drugs and Estrogen. III. Inhibitory Effects of 29 Drugs Reported to Induce Gynecomastia on the Glucuronidation of Estradiol
    1844 Biol. Pharm. Bull. 27(11) 1844—1849 (2004) Vol. 27, No. 11 Studies on the Interactions between Drugs and Estrogen. III. Inhibitory Effects of 29 Drugs Reported to Induce Gynecomastia on the Glucuronidation of Estradiol a b,1) b b, c Takashi SATOH, Yuki TOMIKAWA, Kaori TAKANASHI, Shinji ITOH, * Shungo ITOH, and b Itsuo YOSHIZAWA a Yakuhan Pharmaceutical Co., Ltd.; Kitahiroshima, Hokkaido 061–1111, Japan: b Hokkaido College of Pharmacy; Otaru, Hokkaido 047–0264, Japan: and c Japan Seamen-Relief-Association Otaru Hospital; 1–7–10 Ironai, Otaru, Hokkaido 047–0031, Japan. Received July 5, 2004; accepted August 27, 2004 To determine the inhibition effects of drugs on the glucuronidation of estradiol (E2), 29 drugs that have been reported to induce gynecomastia were examined in the presence of UDP-glucuronic acid using human hepatic microsomes (pooled) as the enzyme source. The percentage inhibition of the E2 glucuronidation was determined at drug concentrations of 1 mM (approximate therapeutic concentration) and 100 mM (non-clinical overdose con- centration) based on the rate constants for the 3- and 17-glucuronidation of E2 (11.2 and 2.52 pmol/min/mg pro- tein, respectively). The only drug that exhibited 50% or higher inhibition of the 3-glucuronidation at a concen- tration of 1 mM was manidipine (54.4%). When the concentration was 100 mM, manidipine exhibited 100% inhibi- tion of the 3-glucuronidation, and other drugs that exhibited 50% or higher inhibition of the 3-glucuronidation were nicardipine (92%), nisoldipine (90%), nifedipine (84%), domperidone (81%), tacrolimus (80%), nitrendip- ine (77%) and ketoconazole (69%).
    [Show full text]
  • Systemic Effect of Inhaled Corticosteroids on Adrenal
    Issa-El-Khoury et al. Allergy, Asthma & Clinical Immunology (2015) 11:9 DOI 10.1186/s13223-015-0075-z ALLERGY, ASTHMA & CLINICAL IMMUNOLOGY POSITION ARTICLE AND GUIDELINES Open Access CSACI position statement: systemic effect of inhaled corticosteroids on adrenal suppression in the management of pediatric asthma Karine Issa-El-Khoury1, Harold Kim2,3, Edmond S Chan4, Tim Vander Leek5 and Francisco Noya1* Abstract Asthma is a chronic inflammatory disease of the airways that affects a growing number of children and adolescents. Inhaled corticosteroids (ICS) are the mainstay of treatment in persistent asthma, with a stepwise approach to increasing doses of ICS depending on asthma severity and control. ICS have known local and systemic side effects, of which adrenal suppression is still under-recognized. The latter is associated with chronic exposure and higher doses, although it has rarely been reported in children receiving low doses for a short period of time. The Canadian Society of Allergy and Clinical Immunology (CSACI) therefore recommends that physicians screen for adrenal suppression in children receiving high doses for more than 6 months and to consider screening those on medium dose if the risk is deemed higher by factors that increase an individual’s systemic corticosteroid exposure. Morning serum cortisol level can be used as a screening tool and abnormal results or normal results with a high index of suspicion should be confirmed with low-dose ACTH stimulation tests. Keywords: Asthma, Inhaled corticosteroids, Fluticasone, Adrenal suppression Background reducing asthma mortality. Most patients can achieve Asthma affects about 10% of the Canadian population, and asthma control using relatively low doses of ICS, which 50-80% of children affected develop it before the age of 5 will produce maximum or near-maximum clinical benefit, years [1].
    [Show full text]
  • Areas of Future Research in Fibroid Therapy
    9/18/18 Cumulative Incidence of Fibroids over Reproductive Lifespan RFTS Areas of Future Research Blacks Blacks UFS Whites in Fibroid Therapy CARDIA Age 33-46 William H. Catherino, MD, PhD Whites Professor and Chair, Research Division Seveso Italy Uniformed Services University Blacks Whites Associate Program Director Sweden/Whites (Age 33-40) Division of REI, PRAE, NICHD, NIH The views expressed in this article are those of the author(s) and do not reflect the official policy or position of the Department of the Army, Department of Defense, or the US Government. Laughlin Seminars Reprod Med 2010;28: 214 Fibroids Increase Miscarriage Rate Obstetric Complications of Fibroids Complication Fibroid No Fibroid OR Abnormal labor 49.6% 22.6% 2.2 Cesarean Section 46.2% 23.5% 2.0 Preterm delivery 13.8% 10.7% 1.5 BreecH position 9.3% 4.0% 1.6 pp Hemorrhage 8.3% 2.9% 2.2 PROM 4.2% 2.5% 1.5 Placenta previa 1.7% 0.7% 2.0 Abruption 1.4% 0.7% 2.3 Guben Reprod Biol Odds of miscarriage decreased with no myoma comparedEndocrinol to myoma 2013;11:102 Biderman-Madar ArcH Gynecol Obstet 2005;272:218 Ciavattini J Matern Fetal Neonatal Med 2015;28:484-8 Not Impacting the Cavity Coronado Obstet Gynecol 2000;95:764 Kramer Am J Obstet Gynecol 2013;209:449.e1-7 Navid Ayub Med Coll Abbottabad 2012;24:90 Sheiner J Reprod Med 2004;49:182 OR = 0.737 [0.647, 0.840] Stout Obstet Gynecol 2010;116:1056 Qidwai Obstet Gynecol 2006;107:376 1 9/18/18 Best Studied Therapies Hysterectomy Option over Time Surgical Radiologic Medical >100 years of study Hysterectomy Open myomectomy GnRH agonists 25-34 years of study Endometrial Ablation GnRH agonists 20-24 years of study Laparoscopic myomectomy Uterine artery embolization Retinoic acid 10-19 years of study Uterine artery obstruction SPRMs: Mifepristone, ulipristal Robotic myomectomy GnRH antagonists 5-9 years of study Cryomyolysis MRI-guided high frequency ultrasound SPRMs: Asoprisnil, Telapristone, Laparoscopic ablation Vilaprisan SERMs: Tamoxifen, Raloxifene, Letrozole, Genistein Pitter MC, Simmonds C, Seshadri-Kreaden U, Hubert HB.
    [Show full text]
  • Understanding Drug-Drug Interactions Due to Mechanism-Based Inhibition in Clinical Practice
    pharmaceutics Review Mechanisms of CYP450 Inhibition: Understanding Drug-Drug Interactions Due to Mechanism-Based Inhibition in Clinical Practice Malavika Deodhar 1, Sweilem B Al Rihani 1 , Meghan J. Arwood 1, Lucy Darakjian 1, Pamela Dow 1 , Jacques Turgeon 1,2 and Veronique Michaud 1,2,* 1 Tabula Rasa HealthCare Precision Pharmacotherapy Research and Development Institute, Orlando, FL 32827, USA; [email protected] (M.D.); [email protected] (S.B.A.R.); [email protected] (M.J.A.); [email protected] (L.D.); [email protected] (P.D.); [email protected] (J.T.) 2 Faculty of Pharmacy, Université de Montréal, Montreal, QC H3C 3J7, Canada * Correspondence: [email protected]; Tel.: +1-856-938-8697 Received: 5 August 2020; Accepted: 31 August 2020; Published: 4 September 2020 Abstract: In an ageing society, polypharmacy has become a major public health and economic issue. Overuse of medications, especially in patients with chronic diseases, carries major health risks. One common consequence of polypharmacy is the increased emergence of adverse drug events, mainly from drug–drug interactions. The majority of currently available drugs are metabolized by CYP450 enzymes. Interactions due to shared CYP450-mediated metabolic pathways for two or more drugs are frequent, especially through reversible or irreversible CYP450 inhibition. The magnitude of these interactions depends on several factors, including varying affinity and concentration of substrates, time delay between the administration of the drugs, and mechanisms of CYP450 inhibition. Various types of CYP450 inhibition (competitive, non-competitive, mechanism-based) have been observed clinically, and interactions of these types require a distinct clinical management strategy. This review focuses on mechanism-based inhibition, which occurs when a substrate forms a reactive intermediate, creating a stable enzyme–intermediate complex that irreversibly reduces enzyme activity.
    [Show full text]
  • Connecticut Medicaid
    ACNE AGENTS, TOPICAL ‡ ANGIOTENSIN MODULATOR COMBINATIONS ANTICONVULSANTS, CONT. CONNECTICUT MEDICAID (STEP THERAPY CATEGORY) AMLODIPINE / BENAZEPRIL (ORAL) LAMOTRIGINE CHEW DISPERS TAB (not ODT) (ORAL) (DX CODE REQUIRED - DIFFERIN, EPIDUO and RETIN-A) AMLODIPINE / OLMESARTAN (ORAL) LAMOTRIGINE TABLET (IR) (not ER) (ORAL) Preferred Drug List (PDL) ACNE MEDICATION LOTION (BENZOYL PEROXIDE) (TOPICAL)AMLODIPINE / VALSARTAN (ORAL) LEVETIRACETAM SOLUTION, IR TABLET (not ER) (ORAL) • The Connecticut Medicaid Preferred Drug List (PDL) is a BENZOYL PEROXIDE CREAM, WASH (not FOAM) (TOPICAL) OXCARBAZEPINE TABLET (ORAL) listing of prescription products selected by the BENZOYL PEROXIDE 5% and 10% GEL (OTC) (TOPICAL) ANTHELMINTICS PHENOBARBITAL ELIXIR, TABLET (ORAL) Pharmaceutical and Therapeutics Committee as efficacious, BENZOYL PEROXIDE 6% CLEANSER (OTC) (TOPICAL) ALBENDAZOLE TABLET (ORAL) PHENYTOIN CHEW TABLET, SUSPENSION (ORAL) safe and cost effective choices when prescribing for HUSKY CLINDAMYCIN PH 1% PLEGET (TOPICAL) BILTRICIDE TABLET (ORAL) PHENYTOIN SOD EXT CAPSULE (ORAL) A, HUSKY C, HUSKY D, Tuberculosis (TB) and Family CLINDAMYCIN PH 1% SOLUTION (not GEL or LOTION) (TOPICAL)IVERMECTIN TABLET (ORAL) PRIMIDONE (ORAL) Planning (FAMPL) clients. CLINDAMYCIN / BENZOYL PEROXIDE 1.2%-5% (DUAC) (TOPICAL) SABRIL 500 MG POWDER PACK (ORAL) • Preferred or Non-preferred status only applies to DIFFERIN 0.1% CREAM (TOPICAL) (not OTC GEL) (DX CODE REQ.) ANTI-ALLERGENS, ORAL SABRIL TABLET (ORAL) those medications that fall within the drug classes DIFFERIN
    [Show full text]
  • Auspar Attachment 1: Product Information for Progesterone
    Attachment 1: Product information for AusPAR - ORIPRO - Progesterone - Orion Laboratories Ltd (T/A Perrigo Australia) - PM-2018-04477-1-5 FINAL 7 February 2020. This is the Product Information that was approved with the submission described in this AusPAR. It may have been superseded. For the most recent PI, please refer to the TGA website at <https://www.tga.gov.au/product-information-pi> AUSTRALIAN PRODUCT INFORMATION – ORIPRO® (PROGESTERONE) PESSARIES 1 NAME OF THE MEDICINE Progesterone 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Oripro Pessaries contain as active substance 100mg or 200mg of progesterone (micronized) in hard fat. 3 PHARMACEUTICAL FORM Vaginal Pessaries - Opaque, bullet-shaped waxy, solid masses. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Oripro Pessaries are indicated for: 1. Assisted reproductive technology (ART) treatment of infertile women with progesterone deficiency, requiring progesterone supplementation or replacement to support embryo implantation and maintain initial pregnancy. 2. Prevention of preterm birth in singleton pregnancies at risk due to; · Shortened cervix 1 Attachment 1: Product information for AusPAR - ORIPRO - Progesterone - Orion Laboratories Ltd (T/A Perrigo Australia) - PM-2018-04477-1-5 FINAL 7 February 2020. This is the Product Information that was approved with the submission described in this AusPAR. It may have been superseded. For the most recent PI, please refer to the TGA website at <https://www.tga.gov.au/product-information-pi> The dosage of progesterone for prevention of preterm birth is 200 mg daily (at night). Treatment can be initiated during the second trimester (16-24 weeks gestation) and is to be continued to the end of the 36th week of gestation or until delivery.
    [Show full text]